3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
4
Completed
4
Unknown
2
Suspended
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
55
Leukemia, Myeloid, Acute
38
Breast Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
35
Multiple Myeloma
31
Lymphoma, Non-Hodgkin
29
Burkitt Lymphoma
29
Lymphoma
27
Myelodysplastic Syndromes
25
Triple Negative Breast Neoplasms
23
Recurrence
23
Hematologic Neoplasms
22
Lymphoma, B-Cell
21
Lymphoma, Follicular
20
Melanoma
16
Ovarian Neoplasms
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Neoplasm Metastasis
14
Leukemia
14
Hodgkin Disease
13
Neoplasms
12
Leukemia, Biphenotypic, Acute
12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Pancreatic Neoplasms
11
Neuroblastoma
11
Leukemia, Myelomonocytic, Chronic
11
Lymphoma, Mantle-Cell
10
Graft vs Host Disease
10
Carcinoma, Non-Small-Cell Lung
10
Lymphoma, T-Cell, Peripheral
9
Interventions
pembrolizumab
16
Radiotherapy
15
Drug Therapy
14
Paclitaxel
13
Cisplatin
12
Carboplatin
10
Immunotherapy
9
Esophagectomy
9
Radiation
8
Fluorouracil
8
Surgical Procedures, Operative
7
Capecitabine
7
Blood Specimen Collection
7
Oxaliplatin
6
Nivolumab
6
Immune Checkpoint Inhibitors
6
Chemoradiotherapy
6
nimotuzumab
5
Trastuzumab
5
130-nm albumin-bound paclitaxel
5
sintilimab
4
camrelizumab
4
Leucovorin
4
trastuzumab deruxtecan
3
tislelizumab
3
patritumab deruxtecan
3
Surveys and Questionnaires
3
Endoscopy
3
Bevacizumab
3
toripalimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Esophageal Neoplasms
×
Cyclophosphamide
×
Clear all
NCT06532799
2024-11-12
BAH250
Essen Biotech
Phase 1/2
Recruiting
75 enrolled